These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 28035434)

  • 1. Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy.
    Dlouhy I; Torrente MÁ; Lens S; Rovira J; Magnano L; Giné E; Delgado J; Balagué O; Martínez A; Campo E; Forns X; Sánchez-Tapias JM; López-Guillermo A
    Ann Hematol; 2017 Mar; 96(3):405-410. PubMed ID: 28035434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.
    Salah-Eldin MA; Ebrahim MA; El-Sadda W
    Ann Hematol; 2014 Nov; 93(11):1903-11. PubMed ID: 24951125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index.
    Chen YY; Huang CE; Liang FW; Lu CH; Chen PT; Lee KD; Chen CC
    Cancer Epidemiol; 2015 Jun; 39(3):382-7. PubMed ID: 25899771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus and diffuse large B-cell lymphoma: Pathogenesis, behavior and treatment.
    Visco C; Finotto S
    World J Gastroenterol; 2014 Aug; 20(32):11054-61. PubMed ID: 25170194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era.
    Zaky AH; Bakry R; El-sayed MI; Elwanis MA; Nabih O
    Hematology; 2014 Oct; 19(7):412-6. PubMed ID: 24620947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
    Nishikawa H; Tsudo M; Osaki Y
    Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy.
    Chen TT; Chiu CF; Yang TY; Lin CC; Sargeant AM; Yeh SP; Liao YM; Bai LY
    Leuk Res; 2015 Feb; 39(2):151-6. PubMed ID: 25524176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients.
    Elbedewy TA; Elashtokhy HEA; Abd-Elsalam S; Suliman MA
    Curr Cancer Drug Targets; 2020; 20(8):638-645. PubMed ID: 32392114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients.
    Hosry J; Miranda RN; Samaniego F; Economides MP; Torres HA
    Int J Cancer; 2018 Mar; 142(5):940-948. PubMed ID: 29047108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis.
    Ennishi D; Maeda Y; Niitsu N; Kojima M; Izutsu K; Takizawa J; Kusumoto S; Okamoto M; Yokoyama M; Takamatsu Y; Sunami K; Miyata A; Murayama K; Sakai A; Matsumoto M; Shinagawa K; Takaki A; Matsuo K; Kinoshita T; Tanimoto M
    Blood; 2010 Dec; 116(24):5119-25. PubMed ID: 20823454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
    Besson C; Canioni D; Lepage E; Pol S; Morel P; Lederlin P; Van Hoof A; Tilly H; Gaulard P; Coiffier B; Gisselbrecht C; Brousse N; Reyes F; Hermine O;
    J Clin Oncol; 2006 Feb; 24(6):953-60. PubMed ID: 16418500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
    Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
    Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study.
    Michot JM; Canioni D; Driss H; Alric L; Cacoub P; Suarez F; Sibon D; Thieblemont C; Dupuis J; Terrier B; Feray C; Tilly H; Pol S; Leblond V; Settegrana C; Rabiega P; Barthe Y; Hendel-Chavez H; Nguyen-Khac F; Merle-Béral H; Berger F; Molina T; Charlotte F; Carrat F; Davi F; Hermine O; Besson C;
    Am J Hematol; 2015 Mar; 90(3):197-203. PubMed ID: 25417909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the presence of hepatitis virus B and C influence the evolution of diffuse large B-cell lymphoma?
    Rubio J; Franco F; Sánchez A; Cantos B; Méndez M; Calvo V; Maximiano C; Perez D; Millán I; Sánchez-Beato M; Provencio M
    Leuk Lymphoma; 2015 Jun; 56(6):1686-90. PubMed ID: 25219591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
    Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
    Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
    Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
    Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of BAFF-R, but not BAFF, is an independent prognostic factor in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Wang Y; Li YJ; Jiang WQ; Rao HL; Huang JJ; Xia Y; Bi X; Sun P; Huang HQ; Lin TY; Guan ZZ; Li ZM
    Ann Hematol; 2015 Nov; 94(11):1865-73. PubMed ID: 26327569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological features and outcome of diffuse large B-cell lymphoma associated with hepatitis C virus in elderly patients: Results of the prospective 'Elderly Project' by the Fondazione Italiana Linfomi.
    Arcari A; Tabanelli V; Merli F; Marcheselli L; Merli M; Balzarotti M; Zilioli VR; Fabbri A; Cavallo F; Casaluci GM; Tucci A; Puccini B; Pennese E; Di Rocco A; Zanni M; Flenghi L; Gini G; Sartori R; Chiappella A; Usai SV; Tani M; Marino D; Arcaini L; Vallisa D; Spina M
    Br J Haematol; 2023 May; 201(4):653-662. PubMed ID: 36733229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis.
    Millar A; Ellis M; Mollee P; Cochrane T; Fletcher J; Caudron A; Webster B; Trotman J
    Intern Med J; 2015 Nov; 45(11):1147-53. PubMed ID: 26337606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
    Ghesquieres H; Slager SL; Jardin F; Veron AS; Asmann YW; Maurer MJ; Fest T; Habermann TM; Bene MC; Novak AJ; Mareschal S; Haioun C; Lamy T; Ansell SM; Tilly H; Witzig TE; Weiner GJ; Feldman AL; Dogan A; Cunningham JM; Olswold CL; Molina TJ; Link BK; Milpied N; Cox DG; Salles GA; Cerhan JR
    J Clin Oncol; 2015 Nov; 33(33):3930-7. PubMed ID: 26460308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.